関: Maxalt、rizatriptan benzoate

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/01/27 20:37:28」(JST)

wiki en

Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt)

Use

Rizatriptan is used to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks.

Contraindications

coronary artery disease
use of monoamine oxidase inhibitors

Adverse effects

Severe:

serotonin syndrome when used with MAOIs
coronary artery vasospasm
transient myocardial ischemia
myocardial infarction
ventricular tachycardia
ventricular fibrillation
hypertensive crisis

Atypical sensations:

paresthesia

Cardiovascular:

palpitations
syncope
hypertension
hypotension

Ear, nose, and throat:

tinnitus
sinusitis
allergic rhinitis
upper respiratory tract inflammation

Gastrointestinal:

diarrhea

Muscular:

myalgia

Neurological:

phonophobia
photophobia

Respiratory:

dyspnea

Skin:

sweating

Miscellaneous:

hypersensitivity

References

External links

Maxalt website by Merck & Co.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における片頭痛の急性期治療 acute treatment of migraine in adults
2. 小児における片頭痛の急性期治療 acute treatment of migraine in children
3. 性行為に伴う一次性頭痛 primary headache associated with sexual activity
4. 妊娠中および出産後の女性における頭痛 headache in pregnant and postpartum women
5. 前庭片頭痛 vestibular migraine

English Journal

Development and gamma-scintigraphy study of Hibiscus rosasinensis polysaccharide-based microspheres for nasal drug delivery.

Sharma N1,2, Tyagi S2, Gupta SK2, Kulkarni GT3, Bhatnagar A4, Kumar N4.
Drug development and industrial pharmacy.Drug Dev Ind Pharm.2016 Nov;42(11):1763-71. doi: 10.3109/03639045.2016.1173050. Epub 2016 Apr 19.
OBJECTIVE: This work describes the application of natural plant polysaccharide as pharmaceutical mucoadhesive excipients in delivery systems to reduce the clearance rate through nasal cavity.METHODS: Novel natural polysaccharide (Hibiscus rosasinensis)-based mucoadhesive microspheres were prepared b
PMID 27032438

Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine.

Kacperski J1,2, Hershey AD3,4.
CNS drugs.CNS Drugs.2016 Sep;30(9):837-44. doi: 10.1007/s40263-016-0375-y.
Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our cu
PMID 27503180

Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study.

Ferrari A1, Baraldi C2, Licata M3, Vandelli D3, Marchesi F3, Palazzoli F3, Verri P3, Rustichelli C4, Giuliani E5, Silingardi E6.
European journal of clinical pharmacology.Eur J Clin Pharmacol.2016 Sep;72(9):1075-81. doi: 10.1007/s00228-016-2074-5. Epub 2016 May 31.
PURPOSE: The aim of this study is to evaluate the detection rate of almotriptan, eletriptan, frovatriptan, sumatriptan, rizatriptan, and zolmitriptan in the hair of migraineurs taking these drugs; the degree of agreement between type of self-reported triptan and triptan found in hair; if the concent
PMID 27245458

Japanese Journal

ガバペンチンにより軽減した薬物乱用頭痛の1 症例

境徹也,澄川耕二
日本ペインクリニック学会誌 20(4), 484-487, 2013
薬物乱用頭痛とは，頭痛治療薬を頻用する結果生じる難治性の頭痛である．今回，複数の頭痛治療薬の頻用が誘因と疑われた薬物乱用頭痛に，ガバペンチンが有効であった症例を経験した．症例は50歳，女性で，中学生の頃から片頭痛を自覚し，市販複合鎮痛薬にて自己対処していた．しかし，12年前に市販複合鎮痛薬を毎日内服するようになり，6年前よりリザトリプタンを毎日，ロキソプロフェンを月に10日以上使用するほど頭痛は悪 …
NAID 130003375370

脳神経外科医が知っておくべき頭痛の知識

間中信也
脳神経外科ジャーナル = Japanese journal of neurosurgery 21(10), 771-778, 2012-10-20
頭痛の診療は, 国際頭痛分類第2版と, 慢性頭痛の診療ガイドラインを活用して行う. 片頭痛には多くの急性期治療と予防療法が存在する. トリプタン (セロトニン1B/1D受容体作動薬) は片頭痛の特異的治療薬であり, 現在 (2011年9月), スマトリプタン, ゾルミトリプタン, エレトリプタン, リザトリプタン, ナラトリプタンの5種類, 錠剤, 口腔錠, 点鼻液, 皮下注射液ののべ10製剤が …
NAID 10031131642

トリプタンおよびCGRP受容体アンタゴニスト

根来清
臨床神経学 52(11), 971-972, 2012
… In several comparative studies of telcagepant and triptans, telcegepant did not appeared more effective than zolmitriptan or rizatriptan, although it had fewer triptan-related adverse events and drug-related adverse enents. …
NAID 130004505228

Related Pictures

★リンクテーブル★

リンク元	「リザトリプタン」「Maxalt」
拡張検索	「rizatriptan benzoate」

「リザトリプタン」

Rizatriptan
Systematic (IUPAC) name
	N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Clinical data
Trade names	Maxalt
AHFS/Drugs.com	monograph
MedlinePlus	a601109
Pregnancy cat.	C
Legal status	℞ Prescription only
Routes	Oral
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	by monoamine oxidase
Half-life	2–3 hours
Excretion	82% urine; 12% faeces
Identifiers
CAS number	145202-66-0
ATC code	N02CC04
PubChem	CID 5078
IUPHAR ligand	51
DrugBank	DB00953
ChemSpider	4900
UNII	WR978S7QHH
KEGG	D00675
ChEBI	CHEBI:48273
ChEMBL	CHEMBL905
Chemical data
Formula	C15H19N5
Mol. mass	269.345 g/mol
	SMILES n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C;
	InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 ; Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N ;
(what is this?) (verify);